Holen Sie sich die Stockscreener-App
9.50
0.85%
0.08
Handel nachbörslich:
9.52
0.02
+0.21%
Schlusskurs vom Vortag:
$9.42
Offen:
$9.48
24-Stunden-Volumen:
3.27M
Relative Volume:
1.17
Marktkapitalisierung:
$967.56M
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.7336
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
-6.86%
1M Leistung:
-27.65%
6M Leistung:
-65.28%
1J Leistung:
-63.09%
1-Tages-Spanne:
$9.32
$9.6887
1-Wochen-Bereich:
$9.25
$10.39
52-Wochen-Spanne:
$9.25
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.50 | 967.56M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
2025-01-20 | Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
Avanza Fonder AB Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc. - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Intellia Loses 21.6% in a Week: How Should You Play the Stock? - MSN
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential (NASDAQ:EDIT) - Seeking Alpha
2025-01-17 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:NTLA | Press Release - Stockhouse Publishing
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK - Yahoo Finance
(NTLA) Technical Pivots with Risk Controls - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation - Markets Insider
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
Intellia to submit gene-editing therapy NTLA-2002 to FDA in 2026 - Angioedema News Today
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out - Markets Insider
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out - Markets Insider
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade) - Seeking Alpha
2025-01-14 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out | NDAQ:NTLA | Press Release - Stockhouse Publishing
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $12.00 by Analysts at The Goldman Sachs Group - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect - AccessWire
Intellia Therapeutics - The Pharma Letter
Intellia Therapeutics: Buying The Path To Commercialization (NASDAQ:NTLA) - Seeking Alpha
13 Analysts Have This To Say About Intellia Therapeutics - Benzinga
Intellia Therapeutics (NASDAQ:NTLA) Given New $40.00 Price Target at Oppenheimer - MarketBeat
Intellia stock target cut at Oppenheimer on program discontinuations - Investing.com
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Intellia Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital - Yahoo Finance
Insider Sellers Might Regret Selling Intellia Therapeutics Shares at a Lower Price Than Current Market Value - Simply Wall St
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo - Yahoo Finance
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA) - MarketBeat
Peering Into Intellia Therapeutics's Recent Short Interest - Benzinga
Gene editing stocks drop as Intellia announces layoffs - MSN
Why Is Intellia Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Intellia stock hits 52-week low at $11.34 amid market challenges By Investing.com - Investing.com South Africa
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low After Analyst Downgrade - MarketBeat
Intellia cuts 27% of workforce as it eyes commercial launch - The Business Journals
Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at BMO Capital Markets - MarketBeat
Intellia stock hits 52-week low at $11.34 amid market challenges - Investing.com
Wells Fargo & Company Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia to stop work on rare disease therapy, lay off staff - BioPharma Dive
CRISPR gene editing company cuts program and jobs - The Pharma Letter
Intellia Therapeutics Restructures to Focus on Late-Stage Programs - TipRanks
Intellia Therapeutics stock falls following strategic reorganization - Investing.com
Intellia Therapeutics stock falls following strategic reorganization By Investing.com - Investing.com Australia
CRISPR biotech Intellia cuts staff as it eyes 2027 launch - pharmaphorum
Intellia to cut 27% of workforce, discontinue NTLA-3001 - MSN
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):